SCHEMBL3483798

SCHEMBL3483798

NS(=O)(=O)c1nnc(-c2ccc(O)cc2)s1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.56
GAA P10253 1/20 0.56
SI P14410 1/20 0.56
MGAM2 Q2M2H8 1/20 0.56
CA2 P00918 12/20 0.50
CA1 P00915 11/20 0.50
CA9 Q16790 7/20 0.50
CA5A P35218 7/20 0.50
CA5B Q9Y2D0 7/20 0.50
CA12 O43570 6/20 0.50
CA7 P43166 4/20 0.50
CA6 P23280 3/20 0.50
CA3 P07451 1/20 0.50
CA4 P22748 5/20 0.44
CA14 Q9ULX7 2/20 0.44
CA13 Q8N1Q1 1/20 0.44
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3484060 0.77 CA1 (0.54) MGAMGAASIMGAM2CA2
SCHEMBL21558840 0.77 CA2 (0.62) CA2CA1CA9CA5ACA5B
SCHEMBL6660612 0.77 GAA (0.72) MGAMGAASIMGAM2HDAC3
SCHEMBL14315046 0.74 CA1 (0.59) CA2CA1CA9CA5ACA5B
SCHEMBL20792740 0.74 CA2 (0.59) CA2CA1CA9CA5ACA5B
SCHEMBL3483840 0.73 RAB9A (0.50) MGAMGAASIMGAM2CA2
SCHEMBL3483079 0.73 RAB9A (0.47) MGAMGAASIMGAM2CA2
SCHEMBL3483249 0.72 GAA (0.41) MGAMGAASIMGAM2HDAC3
SCHEMBL3483253 0.72 GAA (0.41) MGAMGAASIMGAM2HDAC3
SCHEMBL11340093 0.72 MGAM (1.00) MGAMGAASIMGAM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049200-B1 NOVEL INHIBITORS OF BETA-LACTAMASE METHYLGENE INC (CA) 2015-04-29 EP disclosed
US-8440643-B2 Inhibitors of beta-lactamase METHYLGENE INC. (CA) 2013-05-14 US disclosed
US-20100279983-A1 NOVEL INHIBITORS OF BETA-LACTAMASE METHYLGENE INC. 2010-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279983-A1 NOVEL INHIBITORS OF BETA-LACTAMASE MGAM, MGAM2, PGLS MGAM 1/4885GAA 13/4885SI 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.